{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":13,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06578247\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"QuANTUM-WILD","nct_id":"NCT06578247","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=quantum-wild-nct06578247. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"QuANTUM-WILD","arms":[{"description":"Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive quizartinib at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)","label":"Arm A: Quizartinib + Chemotherapy","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)","label":"Arm B: Placebo + Chemotherapy","type":"PLACEBO_COMPARATOR"},{"description":"Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)","label":"Arm C: Quizartinib + Chemotherapy then Placebo Maintenance","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-06-26","type":"ESTIMATED"},"conditions":["Leukemia"],"enrollment":{"count":700,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Quizartinib","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Chemotherapy","type":"DRUG"}],"last_update":"2026-07-02","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-06-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (Arm A vs Arm B)","timeFrame":"Date of first patient randomized to the target number of deaths reached, up to approximately 42 months"}],"references":[{"citation":"Montesinos P, Altman JK, Bullinger L, Cheong JW, Fathi AT, Levis MJ, Luger S, Miyamoto T, Oliva EN, Perl AE, Recher C, Veiga RR, Wang J, Zeidan AM, Liu L, Duong Y, Rohrbach JEC, Inghirami G, Alexis K, Gosberg A, Nahar A, Burns K, Daver N, Erba HP. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Future Oncol. 2026 Jul;22(16):1913-1924. doi: 10.1080/14796694.2026.2689464. Epub 2026 Jul 11.","pmid":"42434847","type":"DERIVED"}],"start_date":{"date":"2024-11-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","url":"https://clinicaltrials.gov/study/NCT06578247"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/quantum-wild-nct06578247"}